# Pulmonx (LUNG) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LUNG
## Company Profile
- Ticker: LUNG
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech, Respiratory
## Stock Data
- Close: 1.98 USD
- Market cap: 68001896.83 USD
- Last updated: 2026-08-05
## Business Overview
### Minimally Invasive COPD Treatment
Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy.
### Zephyr Endobronchial Valve
The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung regions, allowing healthier areas to function more effectively. It has FDA premarket approval, is available in more than 25 countries and is incorporated into treatment guidelines.
### Patient Selection Tools
The Chartis Pulmonary Assessment System evaluates collateral ventilation to help determine whether a patient is suitable for valve therapy. StratX reports use CT imaging to characterize emphysema distribution and fissure completeness.
### Digital Care Support
The LungTraX platform supports patient identification, referral and treatment workflow. Together with Zephyr, Chartis and StratX, it gives Pulmonx an integrated model spanning screening, procedural planning and therapy.
## Why The Stock Is Moving

As of Aug 5, 2026, LUNG closed down 3.88% at $1.98. No new same-company headline was identified in the current news window.

## Future Catalysts

- Pulmonx’s next three months are about Zephyr Valve adoption, new physician-site expansion, and continued lung-volume-reduction procedure growth. The company needs to keep proving that the minimally invasive COPD franchise can keep widening.

## Recent News
- 2026-07-29 20:05 EST — [Pulmonx Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-second-quarter-2026-financial-results-2544a60b) — Source: Pulmonx
- 2026-07-28 20:05 EST — [Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/LUNG/pulmonx-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-ff07eee2) — Source: Pulmonx
- 2026-07-15 20:05 EST — [Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/LUNG/pulmonx-to-report-second-quarter-2026-financial-results-on-july-29-2026-aba8edf7) — Source: Pulmonx
- 2026-06-01 20:05 EST — [Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Pulmonx
- 2026-04-29 20:05 EST — [Pulmonx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-first-quarter-2026-financial-results) — Source: Pulmonx